Table 1.
Clinical characteristics of patients according to PAK6 in the training and validation cohorts.
| Variables | Training cohort (n = 241) |
Validation cohort (n = 342) |
||||||
|---|---|---|---|---|---|---|---|---|
| N | Low PAK6 (%) | High PAK6 (%) | p-Value | N | Low PAK6 (%) | High PAK6 (%) | p-Value | |
| Gender | 0.874 | 0.693 | ||||||
| Male | 173 | 91(52.6%) | 82(47.4%) | 139 | 52(37.4%) | 87(62.6%) | ||
| Female | 68 | 35(51.5%) | 33(48.5%) | 89 | 31(34.8%) | 58(65.2%) | ||
| Age(years) | 0.969 | 0.579 | ||||||
| < 60 | 138 | 72(52.2%) | 66(47.8%) | 140 | 49(35%) | 91(65%) | ||
| ≧ 60 | 103 | 54(52.4%) | 49(47.6%) | 88 | 34(38.6%) | 54(61.4%) | ||
| Tumor size(cm) | 0.341 | 0.391 | ||||||
| < 4 | 123 | 68(55.3%) | 55(44.7%) | 88 | 29(33%) | 59(67%) | ||
| ≧ 4 | 118 | 58(49.2%) | 60(50.8%) | 140 | 54(38.6%) | 86(61.4%) | ||
| Tumor location | 0.547 | 0.474 | ||||||
| Cardia | 49 | 29(59.2%) | 20(40.8%) | 85 | 39(45.9%) | 46(54.1%) | ||
| Body | 39 | 17(43.6%) | 22(56.4%) | 82 | 39(47.6%) | 43(52.4%) | ||
| Antrum | 119 | 62(52.1%) | 57(47.9%) | 145 | 75(51.7%) | 70(48.3%) | ||
| Whole | 34 | 18(52.9%) | 16(47.1%) | 30 | 11(36.7%) | 19(63.3%) | ||
| Differentiation status | 0.111 | 0.057 | ||||||
| Well + Moderate | 124 | 71(57.3%) | 53(42.7%) | 90 | 26(28.9%) | 64(71.1%) | ||
| Poor and undifferentiated | 117 | 55(47.0%) | 62(53.0%) | 138 | 57(41.3%) | 81(58.7%) | ||
| Lauren type | 0.137 | 0.838 | ||||||
| Intestinal type | 194 | 106(54.6%) | 88(45.4%) | 153 | 55(35.9%) | 98(64.1%) | ||
| Diffuse type | 47 | 20(42.6%) | 27(57.4%) | 75 | 28(37.3%) | 47(62.7%) | ||
| CEA | 0.282 | 0.096 | ||||||
| Elevated | 73 | 42(57.5%) | 31(42.5%) | 47 | 22(52.7%) | 25(53.2%) | ||
| Nomal | 168 | 84(50.0%) | 84(50.0%) | 181 | 61(33.7%) | 120(66.3%) | ||
| CA199 | 0.847 | 0.004 | ||||||
| Elevated | 74 | 38(51.4%) | 36(48.6%) | 55 | 29(52.7%) | 26(47.3%) | ||
| Normal | 167 | 88(52.7%) | 79(47.3%) | 173 | 54(31.2%) | 199(68.8%) | ||
| Depth of invasion | 0.347 | 0.619 | ||||||
| T1 + T2 | 50 | 29(58.0%) | 21(42.0%) | 48 | 16(33.3%) | 32(66.7%) | ||
| T3 + T4 | 190 | 96(50.5%) | 94(49.5%) | 180 | 67(37.2%) | 113(62.8%) | ||
| Lymph node metastasis | 0.055 | 0.455 | ||||||
| N0 | 55 | 35(63.6%) | 20(36.4%) | 53 | 17(32.1%) | 36(67.9%) | ||
| N1 + N2 + N3 | 186 | 91(48.9%) | 95(51.1%) | 165 | 66(37.7%) | 109(62.3%) | ||
| TNM stage | 0.013 | 0.009 | ||||||
| I | 12 | 7(58.3%) | 5(41.7%) | 30 | 21(70.0%) | 9(30.0%) | ||
| II | 68 | 46(67.6%) | 22(32.4%) | 70 | 40(57.1%) | 30(42.9%) | ||
| III | 135 | 65(48.1%) | 70(51.9%) | 209 | 91(43.5%) | 118(56.5%) | ||
| IV | 26 | 9(34.6%) | 17(65.4%) | 33 | 12(36.4%) | 21(63.6%) | ||
| Chemotherapy | 0.231 | 0.687 | ||||||
| No | 107 | 61(57.0%) | 46(43.0%) | 138 | 68(49.3%) | 70(50.7%) | ||
| Yes | 134 | 66(49.3%) | 68(50.7%) | 204 | 96(47.1%) | 108(52.9%) | ||